Related Experiment Video
Updated: Oct 2, 2025
05:25
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
2.7K
Cannabidiol (CBD) in Cancer Management
Kylie O'Brien1,2,3,4
1Adelaide Campus, Torrens University, Adelaide, SA 5000, Australia.
Cancers
|February 25, 2022
Summary
Cannabidiol (CBD), a non-intoxicating compound from Cannabis sativa, shows promise in cancer care. Research explores its mechanisms and efficacy in managing cancer and treatment side effects alongside conventional therapies.
Area of Science:
- Pharmacology
- Oncology
- Phytochemistry
Background:
- Cannabis sativa has a long history of medicinal use.
- It contains over 540 metabolites, including key phytocannabinoids like cannabidiol (CBD) and tetrahydrocannabinol (THC).
- CBD lacks the intoxicating effects associated with THC.
Purpose of the Study:
- To explore the potential mechanisms of action of CBD in cancer.
- To review evidence for CBD's efficacy in the integrative management of cancer.
- To assess CBD's role in managing cancer treatment side effects.
Main Methods:
- Review of preclinical and clinical research on CBD and cancer.
- Analysis of proposed molecular pathways for CBD's anti-cancer effects.
- Examination of studies on CBD's impact on cancer-related symptoms and treatment toxicity.
Main Results:
- CBD exhibits a broad spectrum of therapeutic effects relevant to cancer management.
- Evidence suggests potential anti-cancer activities and benefits in alleviating treatment side effects.
- CBD's non-intoxicating profile makes it a suitable candidate for integrative oncology.
Conclusions:
- CBD demonstrates significant potential for integration into orthodox cancer care.
- Further research supports CBD's role in improving patient outcomes and managing adverse effects.
- Cannabidiol offers a promising complementary approach in the holistic management of cancer.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
385
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
385
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:30Cancer Vaccines
542
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
542
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
01:21Cancer Survival Analysis
473
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
473